Story Stocks^®

Intuitive Surgical (ISRG) is trading sharply lower even after topping Q2 estimates, as investors focused less on another strong quarter than on an unchanged outlook that now implies slower second-half da Vinci procedure growth. The company maintained its 2026 worldwide da Vinci procedure growth forecast of approximately 13.5%-15.5%, expects to finish near the midpoint, and paired that with commentary around softer U.S. deferrable procedures and continued China weakness, overshadowing EPS of $2.80 vs. $2.51 consensus, revenue of $2.89 bln vs. $2.83 bln, 16% worldwide procedure growth, 468 da Vinci placements, and a higher full-year non-GAAP gross margin outlook of 68.0%-69.0%.

• Procedure mix: Worldwide da Vinci procedure growth remained healthy, but U.S. growth slowed to 12% from 14% in Q1 as management cited softer demand for deferrable benign procedures and changes in patient coverage dynamics discussed on the call; U.S. bariatric procedures also fell high single digits due to increased GLP-1 adoption.
• Capital demand: System placements rose 18% yr/yr to 468, including 246 da Vinci 5 systems, but roughly half of U.S. placements were upgrades or trades, tempering the near-term installed-base expansion implied by the headline figure even as the overall installed base continued growing at a healthy pace.
• International split: Outside the U.S., procedures grew 21% and placements increased 12%, supported by Japan, India, Europe, and distributor markets, while China remained the primary headwind with just two placements amid weaker tenders, domestic competition, pricing pressure, and policy-related uncertainty.
• Margins: Non-GAAP gross margin improved to 70.0% from 67.9% a year ago, or 68.7% excluding a $36 mln tariff refund benefit, and the company raised its full-year gross margin outlook by 50 bps, although the tariff refund also provided a modest EPS benefit.
• Recurring model: Recurring revenue climbed 19% to $2.47 bln, representing 85% of revenue, with instruments and accessories up 18% and service revenue up 21%, reinforcing that sustained procedure growth—not one quarter of earnings strength—drives the long-term earnings story.

Briefing.com Analyst Insight

The quarter itself was not the problem; expectations were. Given ISRG's premium valuation, investors were looking for another upward revision to procedure growth rather than guidance that mathematically implies slower growth in the back half of the year. Management highlighted continued adoption across da Vinci 5, SP, and the rapidly growing Ion platform, but much of the discussion centered on U.S. procedure softness, coverage uncertainty, and China rather than accelerating utilization. Going forward, investors will be watching whether U.S. procedure growth stabilizes, da Vinci 5 upgrades translate into higher utilization, China tenders recover, and management regains confidence to raise its procedure-growth outlook.